Literature DB >> 26982777

Melanoma patterns of distant relapse: a study of 108 cases from a South Brazilian center.

Rodrigo Kraft Rovere1, Maria Eduarda Pires de Souza1, Danielle Louise da Maia Cidral1, Sara Fernanda Hilgert1, Yasmine Rodrigues Chamse Ddine1, Carlos Efrain Stein2, Giuliano Santos Borges3, Adma Silva de Lima4.   

Abstract

BACKGROUND: The incidence of cutaneous melanoma has increased over the last decades. Recurrences occur most frequently within the first 2-3 years after diagnosis but patients carry a lifelong risk of relapse. Nevertheless, there is no consensus in the literature on what screening tests patients should undergo.
OBJECTIVES: To evaluate the most common melanoma metastasis sites among a South Brazilian population from a city with one of the highest melanoma rates, and establish the best screening method for these patients.
METHODS: A cross-sectional retrospective study of 108 consecutive melanoma patients followed up at a center from 2009 to 2013. Data were collected on demographic and tumoral characteristics, as well as the site of the first diagnosed metastasis.
RESULTS: Patients were divided into 3 groups for analytical purposes: Non-visceral metastases (48% of patients), visceral metastasis (39%) and brain metastasis (13%). We tried to correlate age, gender, mean Breslow thickness, mitosis and death rates with the aforementioned groups but none showed any statistically significant association.
CONCLUSION: Melanoma patients must be monitored to detect early relapse and subsequent effective treatment but the best follow-up strategy remains to be established.

Entities:  

Mesh:

Year:  2016        PMID: 26982777      PMCID: PMC4782645          DOI: 10.1590/abd1806-4841.20163722

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  17 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  Cutaneous melanoma: a 30-year-long epidemiological study conducted in a city in southern Brazil, from 1980-2009.

Authors:  Nilton Naser
Journal:  An Bras Dermatol       Date:  2011 Sep-Oct       Impact factor: 1.896

Review 3.  Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review.

Authors:  Maria Danielsen; Liselotte Højgaard; Andreas Kjær; Barbara Mb Fischer
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

4.  Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines.

Authors:  Emanuela Romano; Michael Scordo; Stephen W Dusza; Daniel G Coit; Paul B Chapman
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

5.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Authors:  Paolo A Ascierto; Dirk Schadendorf; Carola Berking; Sanjiv S Agarwala; Carla Ml van Herpen; Paola Queirolo; Christian U Blank; Axel Hauschild; J Thaddeus Beck; Annie St-Pierre; Faiz Niazi; Simon Wandel; Malte Peters; Angela Zubel; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

6.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 7.  New drugs in melanoma: it's a whole new world.

Authors:  Alexander M M Eggermont; Caroline Robert
Journal:  Eur J Cancer       Date:  2011-07-27       Impact factor: 9.162

Review 8.  Systematic review of medical treatment in melanoma: current status and future prospects.

Authors:  Claus Garbe; Thomas K Eigentler; Ulrich Keilholz; Axel Hauschild; John M Kirkwood
Journal:  Oncologist       Date:  2011-01-06

9.  Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.

Authors:  April K S Salama; Nicole de Rosa; Randall P Scheri; Scott K Pruitt; James E Herndon; Jennifer Marcello; Douglas S Tyler; Amy P Abernethy
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

Review 10.  To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?

Authors:  N J Marciano; T L Merlin; T Bessen; J M Street
Journal:  Int J Clin Pract       Date:  2014-02-18       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.